PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$98.52
-2.66% today
Updated 2026-04-29
Market cap
$6.34B
P/E ratio
—
P/S ratio
137.68x
EPS (TTM)
$-2.05
Dividend yield
—
52W range
$41 – $108
Volume
0.8M
Protagonist Therapeutics Inc (PTGX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $20.06M | $30.93M | $231000.00 | $28.63M | $27.36M | $26.58M | $60.00M | $434.43M | $46.02M |
| Revenue growth (YoY) | — | — | — | — | +54.1% | -99.3% | +12293.1% | -4.4% | -2.8% | +125.7% | +624.1% | -89.4% |
| Cost of revenue | $0.00 | $247000.00 | $317000.00 | $57.55M | $0.00 | — | — | $2.77M | $1.03M | $3.31M | $2.96M | $1.23M |
| Gross profit | $0.00 | $-247000.00 | $-317000.00 | $20.06M | $30.93M | $231000.00 | $28.63M | $27.36M | $26.58M | $60.00M | $434.43M | $44.79M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.3% |
| R&D | $7.46M | $11.83M | $25.70M | $46.18M | $59.50M | $65.00M | $75.98M | $126.01M | $126.22M | $120.16M | $138.13M | $159.29M |
| SG&A | $1.86M | $2.96M | $6.96M | $11.78M | $13.70M | $15.75M | $18.64M | $27.20M | $31.74M | $33.49M | $43.46M | $44.85M |
| Operating income | $-9.32M | $-14.79M | $-32.67M | $-37.90M | $-42.27M | $-80.52M | $-64.52M | $-125.84M | $-131.37M | $-93.65M | $252.84M | $-158.13M |
| Operating margin | — | — | — | -188.9% | -136.7% | -34857.6% | -225.4% | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% |
| EBITDA | $-9.06M | $-14.55M | $-32.35M | $-37.49M | $-41.74M | $-77.01M | $-63.57M | $-123.07M | $-128.00M | $-90.34M | $253.67M | $-128.09M |
| EBITDA margin | — | — | — | -186.9% | -135.0% | -33335.9% | -222.0% | -449.9% | -481.6% | -150.6% | 58.4% | -278.4% |
| EBIT | $-9.32M | $-14.79M | $-32.67M | $-37.90M | $-42.27M | $-77.71M | $-64.52M | $-125.84M | $-131.37M | $-93.65M | $252.84M | $-129.31M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $169000.00 | $598000.00 | $2.48M | $3.37M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-11.07M | $-14.86M | $-37.18M | $-36.96M | $-38.92M | $-77.19M | $-66.15M | $-125.55M | $-123.41M | $-78.95M | $275.19M | $-130.15M |
| Net income growth (YoY) | — | -34.2% | -150.2% | +0.6% | -5.3% | -98.3% | +14.3% | -89.8% | +1.7% | +36.0% | +448.5% | -147.3% |
| Profit margin | — | — | — | -184.2% | -125.9% | -33414.3% | -231.1% | -458.9% | -464.3% | -131.6% | 63.3% | -282.8% |